Companies › Brain Neurotherapy Bio
1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV2-GDNF AAV2-delivered GDNF gene therapy | GDNF | Phase 1 | Parkinson's Disease; Multiple System Atrophy | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04167540 | AAV2-GDNF | Phase 1 | Parkinson's Disease | Neurology | Jun 2027 |
| NCT04680065 | AAV2-GDNF | Phase 1 | Multiple System Atrophy | Neurology | Aug 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.